{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:26:36Z","timestamp":1777922796232,"version":"3.51.4"},"reference-count":94,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:p>\n                    Carbapenem-resistant organisms are increasingly common worldwide, particularly in India and are associated with high mortality rates especially in patients with severe infection such as bacteremia. Existing drugs such as carbapenems and polymyxins have a number of disadvantages, but remain the mainstay of treatment. The tetracycline class of antibiotics was first produced in the 1940s. Minocycline, tetracycline derivative, although licensed for treatment of wide range of infections, has not been considered for treatment of multidrug-resistant organisms until recently and needs further\n                    <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                    studies. Tigecycline, a derivative of minocycline, although with certain disadvantages, has been frequently used in the treatment of carbapenem-resistant organisms. In this article, we review the properties of minocycline and tigecycline, the common mechanisms of resistance, and assess their role in the management of carbapenem-resistant organisms.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2016.0043","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T11:21:14Z","timestamp":1472210474000},"page":"437-446","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":34,"title":["Minocycline and Tigecycline: What Is Their Role in the Treatment of Carbapenem-Resistant Gram\u2013Negative Organisms?"],"prefix":"10.1177","volume":"23","author":[{"given":"Chaitra","family":"Shankar","sequence":"first","affiliation":[{"name":"Christian Medical College and Hospital","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E. B.","family":"Nabarro","sequence":"additional","affiliation":[{"name":"Christian Medical College and Hospital","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Anandan","sequence":"additional","affiliation":[{"name":"Christian Medical College and Hospital","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balaji","family":"Veeraraghavan","sequence":"additional","affiliation":[{"name":"Christian Medical College and Hospital","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,6]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2007.121004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/505494"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nrd1857","article-title":"Tigecycline","volume":"4","author":"Wenzel R.","year":"2005","unstructured":"Wenzel R., , Bate G., , and Kirkpatrick P.. 2005. Tigecycline. Nat. Rev. Drug Discov., 4:809\u2013810.","journal-title":"Nat. Rev. Drug Discov."},{"key":"e_1_3_2_6_2","unstructured":"Tigecycline (Tygacil). 2015. Use During Pregnancy [Internet]. Available at www.drugs.com\/pregnancy\/tigecycline.html"},{"key":"e_1_3_2_7_2","first-page":"47","article-title":"Minocycline hydrochloride: the emerging evidence of its therapeutic value in complicated bacterial infections","volume":"3","author":"Vanderloo J.P.","year":"2011","unstructured":"Vanderloo J.P., , and Rose W.E.. 2011. Minocycline hydrochloride: the emerging evidence of its therapeutic value in complicated bacterial infections. Clin. Med. Rev. Ther., 3:47\u201354.","journal-title":"Clin. Med. Rev. Ther."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1128\/AAC.12.5.642","article-title":"Side effects of minocycline: different dosage regimens","volume":"12","author":"Gump D.W.","year":"1977","unstructured":"Gump D.W., , Ashikaga T., , Fink T.J., , and Radin A.M.. 1977. Side effects of minocycline: different dosage regimens. Antimicrob. Agents Chemother., 12:642\u2013646.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijantimicag.2013.04.014","article-title":"Multidrug-resistant tet(X)-containing hospital isolates in Sierra Leone","volume":"42","author":"Leski T.A.","year":"2013","unstructured":"Leski T.A., , Bangura U., , Jimmy D.H., , Ansumana R., , Lizewski S.E., , Stenger D.A., , Taitti C.R., , and Vora G.J.. 2013. Multidrug-resistant tet(X)-containing hospital isolates in Sierra Leone. Int. J. Antimicrob. Agents., 42:83\u201386.","journal-title":"Int. J. Antimicrob. Agents."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1128\/AAC.33.9.1611","article-title":"Plasmid-mediated Tet M in Haemophilus ducreyi","volume":"33","author":"Roberts M.C.","year":"1989","unstructured":"Roberts M.C. 1989. Plasmid-mediated Tet M in Haemophilus ducreyi. Antimicrob. Agents Chemother., 33:1611\u20131613.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/AAC.34.3.476","article-title":"Characterization of the Tet M determinants in urogenital and respiratory bacteria","volume":"34","author":"Roberts M.C.","year":"1990","unstructured":"Roberts M.C. 1990. Characterization of the Tet M determinants in urogenital and respiratory bacteria. Antimicrob. Agents Chemother., 34:476\u2013478.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0966-842X(94)90610-6","article-title":"Epidemiology of tetracycline-resistance determinants","volume":"2","author":"Roberts M.C.","year":"1994","unstructured":"Roberts M.C. 1994. Epidemiology of tetracycline-resistance determinants. Trends Microbiol., 2:353\u2013357.","journal-title":"Trends Microbiol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.1996.tb00251.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0147-619X(80)90101-8","article-title":"Heterogeneity of tetracycline resistance determinants","volume":"3","author":"Mendez B.","year":"1980","unstructured":"Mendez B., , Tachibana C., , and Levy S.B.. 1980. Heterogeneity of tetracycline resistance determinants. Plasmid., 3:99\u2013108.","journal-title":"Plasmid."},{"issue":"12","key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1099\/13500872-141-12-3015","article-title":"Gene cassettes: a new class of mobile element","volume":"141","author":"Recchia G.D.","year":"1995","unstructured":"Recchia G.D., , and Hall R.M.. 1995. Gene cassettes: a new class of mobile element. Microbiology., 141 (Pt 12):3015\u20133027.","journal-title":"Microbiology."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.10.106"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/AAC.24.6.835","article-title":"Frequency of tetracycline resistance determinant classes among lactose-fermenting coliforms","volume":"24","author":"Marshall B.","year":"1983","unstructured":"Marshall B., , Tachibana C., , and Levy S.B.. 1983. Frequency of tetracycline resistance determinant classes among lactose-fermenting coliforms. Antimicrob. Agents Chemother., 24:835\u2013840.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198206000-00002"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0924-8579(94)90034-5"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200022050-00007"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/bjd.13956","article-title":"Interventions for rosacea: abridged updated Cochrane systematic review including GRADE assessments","volume":"173","author":"Van Zuuren E.J.","year":"2015","unstructured":"Van Zuuren E.J., , and Fedorowicz Z.. 2015. Interventions for rosacea: abridged updated Cochrane systematic review including GRADE assessments. Br. J. Dermatol., 173:651\u2013662.","journal-title":"Br. J. Dermatol."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.137.1.69"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2015.05.018"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/YIC.0000000000000098","article-title":"Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: a double-blind, placebo-controlled, randomized trial","volume":"31","author":"Hamid Emadi-Kouchak P.M.","year":"2016","unstructured":"Hamid Emadi-Kouchak P.M. 2016. Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: a double-blind, placebo-controlled, randomized trial. Int. Clin. Psychopharmacol., 31:20\u201326.","journal-title":"Int. Clin. Psychopharmacol."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.06.021"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00003495-197509040-00005","article-title":"Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use","volume":"9","author":"Brogden R.N.","year":"2012","unstructured":"Brogden R.N., , Speight T.M., , and Avery G.S.. 2012. Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs., 9:251\u2013291.","journal-title":"Drugs."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-2334-11-109","article-title":"Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients","volume":"11","author":"Liang W.","year":"2011","unstructured":"Liang W., , Liu X., , Huang J., , Zhu D., , Li J., , and Zhang J.. 2011. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect. Dis., 11:109.","journal-title":"BMC Infect. Dis."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2125.1991.tb03920.x","article-title":"Penetration of minocycline into lung tissues","volume":"32","author":"Naline E.","year":"1991","unstructured":"Naline E., , Sanceaume M., , Toty L., , Bakdach H., , Pays M., , and Advenier C.. 1991. Penetration of minocycline into lung tissues. Br. J. Clin. Pharmacol., 32:402\u2013404.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066610377975"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-1811-2"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12941-015-0085-1","article-title":"Global in vitro activity of tigecycline and comparator agents: tigecycline evaluation and surveillance trial 2004\u20132013","volume":"14","author":"Hoban D.J.","year":"2015","unstructured":"Hoban D.J., , Reinert R.R., , Bouchillon S.K., , and Dowzicky M.J.. 2015. Global in vitro activity of tigecycline and comparator agents: tigecycline evaluation and surveillance trial 2004\u20132013. Ann. Clin. Microbiol. Antimicrob., 14:27.","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.12.031"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/ipc.0b013e318159d595","article-title":"Minocycline therapy for traumatic wound infections caused by the multidrug-resistant Acinetobacter baumannii-Acinetobacter calcoaceticus complex","volume":"16","author":"Griffith M.E.","year":"2008","unstructured":"Griffith M.E., , Yun H.C., , Horvath L.L., , and Murray C.K.. 2008. Minocycline therapy for traumatic wound infections caused by the multidrug-resistant Acinetobacter baumannii-Acinetobacter calcoaceticus complex. Infect. Dis. Clin. Pract., 16:16\u201319.","journal-title":"Infect. Dis. Clin. Pract."},{"issue":"6","key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1093\/cid\/ciu594","article-title":"Carbapenem-resistance in gram-negative Bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center","volume":"59","author":"Pogue J.M.","year":"2014","unstructured":"Pogue J.M., , Neelakanta A., , Mynatt R.P., , Sharma S., , Lephart P., , and Kaye K.S.. 2014. Carbapenem-resistance in gram-negative Bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin. Infect. Dis., 59(suppl 6):S388\u2013S393.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1586\/14787210.6.5.557","article-title":"Establishing the role of tigecycline in an era of antimicrobial resistance","volume":"6","author":"Schafer J.J.","year":"2008","unstructured":"Schafer J.J., , and Goff D.A.. 2008. Establishing the role of tigecycline in an era of antimicrobial resistance. Expert Rev. Anti. Infect. Ther., 6:557\u2013567.","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4892(01)00081-9"},{"issue":"4","key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/S0924-8579(09)70005-6","article-title":"A review of tigecycline\u2014the first glycylcycline","volume":"32","author":"Peterson L.R.","year":"2008","unstructured":"Peterson L.R. 2008. A review of tigecycline\u2014the first glycylcycline. Int. J. Antimicrob. Agents., 32 Suppl 4:S215\u2013S222.","journal-title":"Int. J. Antimicrob. Agents."},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jac\/dki248","article-title":"Tigecycline","volume":"56","author":"Pankey G.A.","year":"2005","unstructured":"Pankey G.A. 2005. Tigecycline. J. Antimicrob. Chemother., 56:470\u2013480.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/11317100-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of tigecycline","volume":"48","author":"Barbour A.","year":"2009","unstructured":"Barbour A., , Schmidt S., , Ma B., , Schiefelbein L., , Rand K.H., , Burkhardt O., , and Derendorf H.. 2009. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin. Pharmacokinet., 48:575\u2013584.","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn250"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1592\/phco.27.6.835","article-title":"Absence of an interaction between tigecycline and digoxin in healthy men","volume":"27","author":"Zimmerman J.J.","year":"2007","unstructured":"Zimmerman J.J., , Harper D.M., , Matschke K., , Speth J.L., , Raible D.G., , and Fruncillo R.J.. 2007. Absence of an interaction between tigecycline and digoxin in healthy men. Pharmacotherapy., 27:835\u2013844.","journal-title":"Pharmacotherapy."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bdj.4810049"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.09.005"},{"key":"e_1_3_2_44_2","first-page":"503","article-title":"Are E-test and Vitek2 good choices for tigecycline susceptibility testing when comparing broth microdilution for MDR and XDR Acinetobacter baumannii?","volume":"37","author":"Grandesso S.","year":"2014","unstructured":"Grandesso S., , Sapino B., , Amici G., , Mazzucato S., , Solinas M., , and Gion M.. 2014. Are E-test and Vitek2 good choices for tigecycline susceptibility testing when comparing broth microdilution for MDR and XDR Acinetobacter baumannii?. New Microbiol., 37:503\u2013508.","journal-title":"New Microbiol."},{"issue":"5","key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam","volume":"41","author":"Ellis-Grosse E.J.","year":"2005","unstructured":"Ellis-Grosse E.J., , Babinchak T., , Dartois N., , Rose G., , and Loh E., Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. 2005. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis., 41 Suppl 5:S341\u2013S353.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1086\/431676"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.05.012"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3109\/23744235.2015.1062132","article-title":"Successful use of tigecycline for treatment of culture-negative pyogenic vertebral osteomyelitis","volume":"47","author":"Seyman D.","year":"2015","unstructured":"Seyman D., , Berk H., , Sep\u0131n-Ozen N., , K\u0131z\u0131lates F., , Turk C.C., , Buyuktuna S.A., , and Inan D.. 2015. Successful use of tigecycline for treatment of culture-negative pyogenic vertebral osteomyelitis. Infect. Dis. (Lond)., 47:783\u2013788.","journal-title":"Infect. Dis. (Lond)."},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.12.007"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.12.004"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v65i3.1144"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00404-09"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1128\/AAC.04284-14","article-title":"Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation","volume":"59","author":"Brizendine K.D.","year":"2015","unstructured":"Brizendine K.D., , Richter S.S., , Cober E.D., , and van Duin D.. Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation. 2015. Antimicrob Agents Chemother., 59:553\u2013557.","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/jac\/dku495","article-title":"Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae","volume":"70","author":"van Duin D.","year":"2015","unstructured":"van Duin D., , Cober E., , Richter S.S., , Perez F., , Kalayjian R.C., , Salata R.A., , Evans S., , Fowler V.G.Jr., , Kaye K.S., , and Bonomo R.A.. 2015. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J. Antimicrob. Chemother., 70:1203\u20131211.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"O1117","DOI":"10.1111\/1469-0691.12714","article-title":"Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance","volume":"20","author":"van Duin D.","year":"2014","unstructured":"van Duin D., , Cober E.D., , Richter S.S., , Perez F., , Cline M., , Kaye K.S., , Kalayjian R.C., , Salata R.A., , Evans S.R., , and Fowler V.G.Jr., , and Bonomo R.A.. 2014. Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clin. Microbiol. Infect., 20:O1117\u2013O1120.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2013.837957"},{"key":"e_1_3_2_57_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/INF.0b013e3181c806d8","article-title":"Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline","volume":"29","author":"Jaspan H.B.","year":"2010","unstructured":"Jaspan H.B., , Brothers A.W., , Campbell A.J., , McGuire J.K., , Browd S.R., , Manley T.J., , Pak D., , and Weissman S.J.. 2010. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr. Infect. Dis. J., 29:379\u2013381","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_58_2","doi-asserted-by":"crossref","first-page":"e12287","DOI":"10.5812\/jjm.12287","article-title":"Post neurosurgical meningitis due to colistin heteroresistant Acinetobacter baumanii","volume":"7","author":"Moosavian M.","year":"2014","unstructured":"Moosavian M., , Shoja S., , Nashibi R., , Ebrahimi N., , Tabatabaiefar M.A., , Rostami S., , and Peymani A.. 2014. Post neurosurgical meningitis due to colistin heteroresistant Acinetobacter baumanii. Jundishapur J. Microbiol., 7:e12287.","journal-title":"Jundishapur J. Microbiol."},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M480"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.03.012"},{"key":"e_1_3_2_61_2","first-page":"702910","article-title":"Refractory Clostridium difficile infection successfully treated with tigecycline, rifaximin, and vancomycin","volume":"2012","author":"Lao D","year":"2012","unstructured":"Lao D2nd., , Chiang T., , and Gomez E.. 2012. Refractory Clostridium difficile infection successfully treated with tigecycline, rifaximin, and vancomycin. Case Rep. Med., 2012:702910.","journal-title":"Case Rep. Med."},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2011.616224"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.04.025"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01402-10"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70177-3"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr242"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis270"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2015.08.009"},{"key":"e_1_3_2_69_2","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/jac\/dkr368","article-title":"Comment on: efficacy and safety of tigecycline: a systematic review and meta-analysis","volume":"66","author":"Curcio D.","year":"2011","unstructured":"Curcio D., , and Verde P.E.. 2011. Comment on: efficacy and safety of tigecycline: a systematic review and meta-analysis. J. Antimicrob Chemother., 66:2893\u20132895.","journal-title":"J. Antimicrob Chemother."},{"key":"e_1_3_2_70_2","doi-asserted-by":"crossref","first-page":"e3126","DOI":"10.1097\/MD.0000000000003126","article-title":"Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis","volume":"95","author":"Ni W.","year":"2016","unstructured":"Ni W., , Han Y., , Liu J., , Wei C., , Zhao J., , Cui J., , Wang R., , and Liu Y.. 2016. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore)., 95:e3126.","journal-title":"Medicine (Baltimore)."},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.220-229.2005"},{"key":"e_1_3_2_72_2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01615-10","article-title":"Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline","volume":"56","author":"Bhavnani S.M.","year":"2012","unstructured":"Bhavnani S.M., , Rubino C.M., , Hammel J.P., , Forrest A., , Dartois N., , Cooper C.A., , Korth-Bradley J., , and Ambrose P.G.. 2012. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob. Agents Chemother., 56:1065\u20131072.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_73_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijantimicag.2009.01.015","article-title":"Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint","volume":"34","author":"Burkhardt O.","year":"2009","unstructured":"Burkhardt O., , Rauch K., , Kaever V., , Hadem J., , Kielstein J.T., , and Welte T.. 2009. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int. J. Antimicrob. Agents., 34:101\u2013102.","journal-title":"Int. J. Antimicrob. Agents."},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01232-12"},{"key":"e_1_3_2_75_2","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"Pascale G.D.","year":"2014","unstructured":"Pascale G.D., , Montini L., , Pennisi M.A., , Bernini V., , Maviglia R., , Bello G., , Spanu T., , Tumbarello M., , and Antonelli M.. 2014. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit. Care., 18:R90.","journal-title":"Crit. Care."},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc13858"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.006"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70850-3"},{"key":"e_1_3_2_79_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13756-015-0043-x","article-title":"Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations","volume":"4","author":"Teo J.","year":"2015","unstructured":"Teo J., , Lim T.-P., , Hsu L.-Y., , Tan T.-Y., , Sasikala S., , Hon P.-Y., , Kwa A.L., , and Apisarntharanak A.. 2015. Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. Antimicrob Resist. Infect. Control., 4:2.","journal-title":"Antimicrob Resist. Infect. Control."},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv086"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.05.012"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl224"},{"key":"e_1_3_2_83_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/138920009787048356","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline","volume":"10","author":"Falagas M.E.","year":"2009","unstructured":"Falagas M.E., , Karageorgopoulos D.E., , and Dimopoulos G.. 2009. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr. Drug. Metab., 10:13\u201321.","journal-title":"Curr. Drug. Metab."},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.02.004"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.7.1052"},{"key":"e_1_3_2_86_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.diagmicrobio.2010.02.001","article-title":"Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes","volume":"67","author":"Nguyen M.","year":"2010","unstructured":"Nguyen M., , Eschenauer G.A., , Bryan M., , O'Neil K., , Furuya E.Y., , Della-Latta P., , and Kubin C.J.. 2010. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn. Microbiol. Infect. Dis., 67:180\u2013184.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_87_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2217\/fmb.14.58","article-title":"Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens","volume":"9","author":"Poulakou G.","year":"2014","unstructured":"Poulakou G., , Bassetti M., , Righi E., , and Dimopoulos G.. 2014. Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. Future Microbiol., 9:1053\u20131069.","journal-title":"Future Microbiol."},{"key":"e_1_3_2_88_2","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1128\/JCM.00098-09","article-title":"Detection of plasmid-mediated KPC-producing Klebsiella pneumoniae in Ottawa, Canada: evidence of intrahospital transmission","volume":"47","author":"Goldfarb D.","year":"2009","unstructured":"Goldfarb D., , Harvey S.-B., , Jessamine K., , Jessamine P., , Toye B., , and Desjardins M.. 2009. Detection of plasmid-mediated KPC-producing Klebsiella pneumoniae in Ottawa, Canada: evidence of intrahospital transmission. J. Clin. Microbiol., 47:1920\u20131922.","journal-title":"J. Clin. Microbiol."},{"key":"e_1_3_2_89_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.diagmicrobio.2010.10.013","article-title":"Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections","volume":"69","author":"Neuner E.A.","year":"2011","unstructured":"Neuner E.A., , Yeh J.-Y., , Hall G.S., , Sekeres J., , Endimiani A., , Bonomo R.A., , Shrestha N.K., , Fraser T.G., , and Van Duin D.. 2011. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn. Microbiol. Infect. Dis., 69:357\u2013362.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis588"},{"key":"e_1_3_2_91_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/00365548.2013.861608","article-title":"Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients","volume":"46","author":"Balandin Moreno B.","year":"2014","unstructured":"Balandin Moreno B., , Fern\u00e1ndez Sim\u00f3n I., , Pintado Garc\u00eda V., , S\u00e1nchez Romero I., , Isidoro Fern\u00e1ndez B., , Romera Ortega M.A., , Alc\u00e1ntara Carmona S., , P\u00e9rez Redondo M., , and Galdos Anuncibay P.. 2014. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients. Scand. J. Infect. Dis., 46:175\u2013180.","journal-title":"Scand. J. Infect. Dis."},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.7.980"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2009.02.009"},{"key":"e_1_3_2_94_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-2334-14-102","article-title":"Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis","volume":"14","author":"Chuang Y.-C.","year":"2014","unstructured":"Chuang Y.-C., , Cheng C.-Y., , Sheng W.-H., , Sun H.-Y., , Wang J.-T., , Chen Y.-C., , and Chang C.S.. 2014. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect. Dis., 14:102.","journal-title":"BMC Infect. Dis."},{"key":"e_1_3_2_95_2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3349\/ymj.2012.53.5.974","article-title":"Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection","volume":"53","author":"Shin J.A.","year":"2012","unstructured":"Shin J.A., , Chang Y.S., , Kim H.J., , Kim S.K., , Chang J., , Ahn C.M., , and Byun M.K.. 2012. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection. Yonsei Med. J., 53:974\u2013984.","journal-title":"Yonsei Med. J."}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2016.0043","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2016.0043","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2016.0043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:30:30Z","timestamp":1777667430000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2016.0043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1089\/mdr.2016.0043"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2016.0043","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}